GLP-1 Before Surgery: Anesthesia Risks and When to Stop

One in Eight Americans Now Walk Into Surgery on a GLP-1 Drug

About one in eight U.S. adults — roughly 12% of the population — currently uses a GLP-1 receptor agonist like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), or Trulicity (dulaglutide). That number has climbed fast. A 2024 survey of 236 anesthesiologists found that 65% encounter a patient on one of these drugs at least once a week.

Your anesthesiologist cares about these drugs for one specific reason: GLP-1 medications work partly by slowing how fast food leaves your stomach. That's useful when you're trying to lose weight or control blood sugar — you feel full longer. But when you're going under general anesthesia, food still sitting in your stomach becomes a hazard.

Think of it like a car's fuel tank with a slow drain. Under normal circumstances, the tank empties at a predictable rate, and your pre-surgery fast accounts for that. GLP-1 medications put a partial clamp on the drain. Standard fasting times assume an unobstructed flow. When the drain is slower than expected, the tank might still have fuel in it at go-time.

The specific concern is aspiration — stomach contents flowing backward into the esophagus and then into the lungs while you're unconscious. This can cause aspiration pneumonia, a serious and sometimes fatal complication. The baseline risk of aspiration during surgery is low, estimated at 0.02% to 0.07% of all surgical procedures, but anesthesiologists treat even small risks seriously when the consequence is that severe.

A meta-analysis led by Dr. Thomas R. McCarty at Houston Methodist, covering 36 randomized controlled trials and over 1,500 patients, measured the actual delay: GLP-1 drugs slow solid food emptying by about 36 minutes on average. Liquids were barely affected. That 36-minute number is modest given that standard fasting calls for at least six hours without solid food — but it doesn't tell the whole story, because some patients are affected far more than others.

The delay varies considerably by which GLP-1 drug you take. According to pharmacology data compiled by Mayo Clinic researchers in the Cleveland Clinic Journal of Medicine, dulaglutide (Trulicity) causes the longest delay at around 120 minutes, exenatide at 100–120 minutes, liraglutide at about 70 minutes, and semaglutide (Ozempic/Wegovy) at roughly 60 minutes. A wrinkle worth knowing: the delay tends to be more pronounced when you first start the drug or increase your dose, then diminishes over time through a process called tachyphylaxis at the vagal nerve.

So the practical question facing every surgical team became: do we make patients stop these drugs before surgery, and if so, how far in advance?

How the ASA Went From "Stop Your GLP-1" to "Keep Taking It" in 16 Months

In June 2023, the American Society of Anesthesiologists published its first guidance on GLP-1 drugs and surgery. The recommendation was cautious: hold daily GLP-1 medications on the day of surgery, and hold weekly injections for one full week before. These rules applied regardless of the indication — whether diabetes or weight loss — and regardless of dose or procedure type.

The ASA's own language acknowledged the problem with its recommendation. The evidence base was, in their words, "sparse, limited only to several case reports." No randomized trials. No large observational studies. Just a handful of alarming situations where patients had food in their stomachs despite fasting.

Criticism arrived quickly. Dr. Thomas R. McCarty, the Houston Methodist gastroenterologist whose meta-analysis would later quantify the actual gastric emptying delay, pointed out that the seven-day hold recommendation was "not based on empirical data." Endocrinologists raised a different alarm: for patients with type 2 diabetes, stopping a GLP-1 drug for a week could spike blood glucose into dangerous territory.

The same physician — Dr. Girish P. Joshi, vice chair of ASA's Committee on Practice Parameters — co-authored both the 2023 guidance that said "stop" and the 2024 guidance that said "continue." That's not a contradiction. That's how rapidly the evidence shifted.

By October 2024, the ASA reversed course. A new multi-society guidance — co-signed by the ASA, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — stated that most patients should continue their GLP-1 medications before elective surgery. The October 2024 guidance, as a correction published in the Cleveland Clinic Journal of Medicine confirmed, "no longer recommends routine discontinuation of GLP-1 receptor agonists before anesthesia in most patients."

ASA President Donald E. Arnold, M.D., framed the shift: "In many cases, patients with scheduled procedures should continue taking the drug. Scheduling of elective procedures should integrate awareness of circumstances when the risk of delayed stomach emptying is highest, such as when the patient is just beginning the drug and the dose is being increased."

The 2024 guidance replaced a blanket rule with a risk-stratification approach. Instead of stopping everyone's medication, the team evaluates each patient's individual risk profile and adjusts the pre-surgical plan accordingly.

What SPAQI's 2025 Consensus Actually Recommends

The Society for Perioperative Assessment and Quality Improvement (SPAQI) published its own multidisciplinary consensus statement in the British Journal of Anaesthesia in 2025, and it went further than the ASA guidance in several ways. Led by Dr. Adriana D. Oprea at Yale, the panel included anesthesiologists, endocrinologists, a gastroenterologist, internal medicine physicians, and a representative from the American Association of Clinical Endocrinology.

Their process was rigorous: a systematic literature review registered in PROSPERO (CRD42023438624), followed by a modified Delphi process that took five rounds of voting to reach 100% consensus on all seven final recommendations. That level of agreement across disciplines that often disagree on perioperative management is notable.

The headline recommendation: continue GLP-1 RAs perioperatively in patients without significant gastrointestinal symptoms (Grade B). The SPAQI panel was specific about what counts as "significant" — severe nausea, vomiting, and inability to tolerate oral intake qualify. Feelings of fullness or early satiety do not.

Where SPAQI departed from standard practice was fasting. The standard ASA fasting guideline allows solid food up to 8 hours before surgery. SPAQI said that's not enough for GLP-1 patients. Their data showed that patients fasting for 7 to 18 hours still presented with residual gastric contents. Their recommendation:

What	SPAQI Recommendation	Standard ASA Fasting
Solid food	24 hours before (clear liquids only)	6-8 hours before
High-carb clear liquids (≥10% glucose)	8 hours before	2 hours before
Low-carb clear liquids (<10% glucose)	4 hours before	2 hours before

The third pillar of the SPAQI approach is point-of-care gastric ultrasound. Rather than guessing whether a patient's stomach is empty, the anesthesiologist can check directly on the day of surgery. If the scan shows an empty stomach, the procedure goes forward as planned. If it shows retained contents, the team has options: proceed with full-stomach precautions (rapid-sequence induction, a modified anesthesia technique) or postpone.

For patients with significant GI symptoms, SPAQI recommends referral back to the prescribing physician for diet and medication modifications before scheduling elective surgery. After surgery, both inpatients and outpatients can restart their GLP-1 drug once they resume their usual diet.

The practical implication: if your anesthesiologist follows the SPAQI recommendations, you won't be told to stop your medication. You will be told to eat nothing solid for a full day before surgery, stick to clear liquids, and expect a stomach ultrasound check before you go to the operating room.

14 Days: The Number That Keeps Appearing in the Research

While most guidelines now say "continue your GLP-1 and modify your fasting," a separate line of research has been asking a different question: if you do stop the medication, how long does it take before the stomach returns to normal?

The answer keeps converging on the same number.

At the 2025 Annual Meeting of the American Academy of Orthopaedic Surgeons, Dr. Christopher T. Holland presented a study that tracked semaglutide users undergoing total hip and knee replacement surgery. Using the TriNetX database, the researchers categorized patients by when they last took semaglutide before surgery and compared complication rates against a control group of 206,005 patients who had never taken the drug.

The findings were clean:

Last Dose Before Surgery	Delayed Emergence	Aspiration	Aspiration Pneumonitis	Conversion to Intubation
3 days	Risk factor	Risk factor	Risk factor	Risk factor
5 days	Risk factor	Risk factor	Risk factor	Risk factor
7 days	No risk	Risk factor	No risk	Risk factor
14 days	No risk	No risk	No risk	No risk
30 days	No risk	No risk	No risk	No risk
Did not stop	Highest risk	Highest risk	Highest risk	Highest risk

At 14 days, semaglutide was no longer an independent risk factor for any of the four complications studied. Seven days wasn't enough — aspiration and conversion to intubation remained elevated. And patients who didn't stop at all had the highest complication rates across the board.

Independently, a study of 1,094 semaglutide patients undergoing upper endoscopy (cited in the SPAQI consensus) reached the same conclusion through a different lens. Santos and colleagues found that semaglutide interruption of less than 14 days was insufficient to reduce residual gastric content. Patients needed to stop for more than 14 days without GI symptoms, or more than 21 days if they had symptoms, to reach residual gastric content levels comparable to non-users.

The pharmacology explains why. Semaglutide has a half-life of approximately one week and remains detectable in circulation for up to five weeks after the last injection. At 14 days — two half-lives — roughly 75% of the drug has cleared. The SPAQI panel noted that GLP-1 drugs generally need 4 to 5 half-lives to fully clear, which for weekly semaglutide means 4 to 5 weeks. But 14 days appears to be the point where gastric function has recovered enough to bring aspiration risk back to baseline.

One important caveat: the AAOS study focused specifically on total joint arthroplasty patients. Whether the 14-day threshold applies equally to other surgery types — cardiac, abdominal, outpatient procedures — hasn't been directly tested. The pharmacology suggests it should, but surgical context matters.

A Practical Conversation Guide for Your Pre-Op Appointment

The guidance has changed fast enough that your surgeon or anesthesiologist may be working from older protocols. A 2024 survey found that while 66% of anesthesiologists had read the ASA's 2023 guidance, many expressed confusion about what to do in practice. The 2024 and 2025 updates have likely reached some practitioners but not all.

What to bring up, and how:

Disclose everything. Tell your surgical team and anesthesiologist that you are taking a GLP-1 medication — by brand name and dose. This applies even if you're only taking it for weight loss and not diabetes. The UK's MHRA specifically warned that patients who purchase GLP-1 drugs privately for "aesthetic weight loss" may not volunteer this information unless directly asked. If you're taking tirzepatide (Mounjaro/Zepbound), mention that it's a dual GIP/GLP-1 drug — the combination affects the same gastric pathways.

Tell them where you are in treatment. Whether you're in the dose-escalation phase (the first 4 to 8 weeks of treatment, when doses are being gradually increased) matters a lot. This is the highest-risk period for delayed gastric emptying. Most guidelines recommend deferring elective surgery until the escalation phase is complete and any GI side effects have settled.

Report any GI symptoms honestly. Nausea, vomiting, abdominal pain, bloating, or constipation are all relevant. If you're experiencing these, your anesthesiologist needs to know — and most guidelines recommend waiting until the symptoms resolve before proceeding with elective surgery.

The MHRA advises patients directly: "Take your prescribed medicine(s) as usual and do not stop your treatment without first discussing this with your doctor."

Ask these three questions:

Question	Why It Matters
"Are you following the October 2024 multi-society guidance or the older 2023 recommendation?"	Identifies whether your team is using current protocols
"Will I need to fast from solid food for 24 hours before the procedure?"	Extended fasting is now the standard for GLP-1 patients per SPAQI and ASA 2024
"Will you do a gastric ultrasound before the procedure?"	Point-of-care ultrasound can confirm your stomach is empty, giving everyone confidence to proceed

If your anesthesiologist is uncomfortable proceeding while you remain on the medication, that's a legitimate clinical decision — but you should understand the tradeoff. For patients with type 2 diabetes, stopping a GLP-1 drug risks hyperglycemia, which carries its own surgical risks. The SPAQI consensus noted that perioperative glucose above 200 mg/dL has been associated with postoperative heart attack, kidney injury, neurological complications, and increased mortality.

For more on GLP-1 medication safety in general, see our guide on Ozempic safety and semaglutide side effects. And for a broader perspective on the drug class, our GLP-1 weight loss drugs safety guide covers the fundamentals.

Three Reasons the Rules Keep Shifting — and When They Might Stabilize

If you've been following GLP-1 and surgery guidance, you might feel like the ground keeps moving under you. Stop your medication. No, keep taking it. Fast for 8 hours. Actually, fast for 24. There are structural reasons the recommendations have been volatile, and understanding them helps calibrate your expectations.

Reason one: the drugs are newer than the problem. GLP-1 receptor agonists were introduced in 2005, but their use exploded only after semaglutide's approval for weight loss in 2021. The surgical community went from rarely encountering these patients to seeing them constantly, with 65% of anesthesiologists now managing them weekly. When millions of patients flood operating rooms on a drug class that's been popular for only a few years, the evidence base can't keep up.

Reason two: residual gastric content isn't the same as aspiration. Multiple studies have found that GLP-1 patients are more likely to have food in their stomachs despite standard fasting. But two large meta-analyses totaling over 160,000 patients found that actual aspiration event rates in GLP-1 users are not statistically different from the general population. Having food in your stomach creates a precondition for aspiration, but anesthesiologists have tools to manage it — modified techniques, gastric ultrasound, rapid-sequence induction. The gap between "more residual food" and "more aspiration events" is where much of the disagreement lives.

Reason three: stopping the medication creates its own risks. The 2023 guidance focused narrowly on aspiration risk. The 2024 and 2025 guidance took a wider view. For patients with diabetes, stopping GLP-1 drugs can trigger cardiac decompensation, worsen blood pressure, cause fluid retention, and exacerbate heart failure. And there's a logistical headache: restarting after a multi-week hold often means going back through the dose-escalation phase, which is the highest-risk period for the exact GI side effects everyone is trying to avoid.

The ASA's 2024 guidance also raised an equity concern that earlier documents didn't address: withholding GLP-1 drugs only from overweight and obese patients, without a specific medical risk factor, could constitute weight-based bias or discrimination.

Where does this leave things? The trajectory is toward more permissive guidelines — continue the medication, modify the fasting protocol, check the stomach with ultrasound, and proceed. The UK MHRA's European review concluded that the evidence was too limited to recommend a specific pause time, and that anesthesiologists should retain flexibility for individualized assessment. That principle — individualize rather than mandate — runs through every recent guideline.

What would stabilize the guidance is a randomized controlled trial comparing outcomes in GLP-1 patients who continue their medication (with modified fasting) versus those who stop 14+ days before surgery. That trial doesn't exist yet. Until it does, expect the recommendations to continue evolving as observational data accumulates.

Frequently Asked Questions

Can I take Ozempic or Wegovy the week before my surgery?

According to the October 2024 multi-society guidance and the 2025 SPAQI consensus, most patients can continue their GLP-1 medication as scheduled before surgery. The key adjustment is fasting from solid food for 24 hours before the procedure instead of the standard 6-8 hours. Your anesthesiologist should assess your individual risk factors — GI symptoms, dose level, how long you've been on the medication — before deciding the final plan.

Why did the ASA change its GLP-1 surgery guidance?

The original June 2023 recommendation to stop GLP-1 drugs before surgery was based on limited evidence — primarily case reports. By October 2024, larger studies showed that the actual aspiration risk increase was smaller than initially feared, and that stopping the medication created its own dangers (blood sugar spikes in diabetic patients, logistical challenges of restarting). The ASA partnered with four other medical societies to issue updated guidance reflecting this broader evidence base.

How long does semaglutide stay in your system before surgery?

Semaglutide has a half-life of about one week and can be detected in circulation for up to five weeks after the last injection. Research from the 2025 AAOS annual meeting suggests that 14 days after the last dose is the point where anesthesia-related complication risk returns to baseline levels.

What is a gastric ultrasound and will I need one before surgery?

Point-of-care gastric ultrasound is a bedside scan that lets the anesthesiologist see whether your stomach is empty before administering anesthesia. It takes a few minutes and is non-invasive. Both the SPAQI consensus and the ASA 2024 guidance recommend it for higher-risk GLP-1 patients. Not every facility uses it routinely yet, so it's worth asking your anesthesiologist whether they plan to.

Does Mounjaro (tirzepatide) carry the same surgery risks as Ozempic?

Yes. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and like pure GLP-1 drugs, it slows gastric emptying. The UK MHRA includes both GLP-1 and dual GIP/GLP-1 agonists in its aspiration risk warnings. The same pre-surgical precautions — extended fasting, symptom screening, potential gastric ultrasound — apply to tirzepatide users.